{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T14:30:13Z","timestamp":1769610613774,"version":"3.49.0"},"reference-count":154,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1016\/j.amjmed.2011.10.009","type":"journal-article","created":{"date-parts":[[2011,12,20]],"date-time":"2011-12-20T17:37:48Z","timestamp":1324402668000},"page":"S25-S38","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":63,"special_numbering":"S","title":["Invasive Mycoses: Strategies for Effective Management"],"prefix":"10.1016","volume":"125","author":[{"given":"Dimitrios P.","family":"Kontoyiannis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"suppl","key":"10.1016\/j.amjmed.2011.10.009_bib1","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.amjmed.2011.11.001","article-title":"Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment","volume":"125","author":"Pfaller","year":"2012","journal-title":"Am J Med"},{"key":"10.1016\/j.amjmed.2011.10.009_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/10408410903241444","article-title":"Epidemiology of invasive mycoses in North America","volume":"36","author":"Pfaller","year":"2010","journal-title":"Crit Rev Microbiol"},{"issue":"suppl","key":"10.1016\/j.amjmed.2011.10.009_bib3","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1016\/j.amjmed.2011.10.008","article-title":"Invasive mycoses: diagnostic challenges","volume":"125","author":"Ostrosky-Zeichner","year":"2012","journal-title":"Am J Med"},{"key":"10.1016\/j.amjmed.2011.10.009_bib4","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1600-0609.2009.01391.x","article-title":"Diagnostic challenges and recent advances in the early management of invasive fungal infections","volume":"84","author":"Chandrasekar","year":"2010","journal-title":"Eur J Haematol"},{"issue":"suppl 1","key":"10.1016\/j.amjmed.2011.10.009_bib5","doi-asserted-by":"crossref","first-page":"i15","DOI":"10.1093\/jac\/dkq438","article-title":"Detection and investigation of invasive mould disease","volume":"66","author":"Cuenca-Estrella","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.amjmed.2011.10.009_bib6","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1086\/590004","article-title":"Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis","volume":"47","author":"Chamilos","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.amjmed.2011.10.009_bib7","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1086\/504810","article-title":"Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study","volume":"43","author":"Garey","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.amjmed.2011.10.009_bib8","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1128\/AAC.49.9.3640-3645.2005","article-title":"Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality","volume":"49","author":"Morrell","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.amjmed.2011.10.009_bib9","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1159\/000196477","article-title":"Pulmonary aspergillosis: early diagnosis improves survival","volume":"62","author":"von Eiff","year":"1995","journal-title":"Respiration"},{"key":"10.1016\/j.amjmed.2011.10.009_bib10","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1128\/AAC.00705-08","article-title":"Antifungal therapeutic drug monitoring: established and emerging indications","volume":"53","author":"Andes","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.amjmed.2011.10.009_bib11","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1007\/s12281-010-0023-9","article-title":"Antifungal drug monitoring","volume":"4","author":"Lewis","year":"2010","journal-title":"Curr Fungal Infect Rep"},{"key":"10.1016\/j.amjmed.2011.10.009_bib12","article-title":"Antifungal treatment strategies in patients with haematological diseases or cancer: from prophylaxis to empirical, pre-emptive and targeted therapy","author":"Mikolajewska","year":"2011","journal-title":"Mycoses"},{"key":"10.1016\/j.amjmed.2011.10.009_bib13","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.2165\/00003495-200868140-00002","article-title":"Patients at high risk of invasive fungal infections: when and how to treat","volume":"68","author":"Ruping","year":"2008","journal-title":"Drugs"},{"key":"10.1016\/j.amjmed.2011.10.009_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.medcli.2009.06.066","article-title":"Nosocomial candidemia at a general hospital: prognostic factors and impact of early empiric treatment on outcome (2002\u20132005)","volume":"134","author":"Gomez","year":"2010","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.amjmed.2011.10.009_bib15","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s001340050286","article-title":"Candidemia in non-neutropenic critically ill patients: analysis of prognostic factors and assessment of systemic antifungal therapy","volume":"23","author":"Nolla-Salas","year":"1997","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.amjmed.2011.10.009_bib16","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1097\/MJT.0b013e3181a1afb7","article-title":"The effect of time to antifungal therapy on mortality in candidemia associated septic shock","volume":"16","author":"Patel","year":"2009","journal-title":"Am J Ther"},{"key":"10.1016\/j.amjmed.2011.10.009_bib17","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1086\/597395","article-title":"Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial","volume":"48","author":"Cordonnier","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.amjmed.2011.10.009_bib18","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1086\/496927","article-title":"Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study","volume":"41","author":"Maertens","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.amjmed.2011.10.009_bib19","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1586\/eri.10.16","article-title":"Antifungal prophylaxis and treatment in patients with hematological malignancies","volume":"8","author":"Hwang","year":"2010","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.amjmed.2011.10.009_bib20","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/bmt.2010.256","article-title":"Antifungal prophylaxis in hematopoietic stem cell transplant recipients: the unfinished tale of imperfect success","volume":"46","author":"Kontoyiannis","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.amjmed.2011.10.009_bib21","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1086\/649879","article-title":"Fungal infections in leukemia patients: how do we prevent and treat them?","volume":"50","author":"Leventakos","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"suppl 1","key":"10.1016\/j.amjmed.2011.10.009_bib22","doi-asserted-by":"crossref","first-page":"i37","DOI":"10.1093\/jac\/dkq440","article-title":"Treatment and timing in invasive mould disease","volume":"66","author":"Maertens","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.amjmed.2011.10.009_bib23","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1200\/JCO.2008.20.1178","article-title":"Approaches to the management of invasive fungal infections in hematologic malignancy and hematopoietic cell transplantation","volume":"27","author":"Michallet","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.amjmed.2011.10.009_bib24","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1086\/588300","article-title":"Clinical practice guidelines for the management of blastomycosis: 2008 update by the Infectious Diseases Society of America","volume":"46","author":"Chapman","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.amjmed.2011.10.009_bib25","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1086\/496991","article-title":"Coccidioidomycosis","volume":"41","author":"Galgiani","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.amjmed.2011.10.009_bib26","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1086\/522765","article-title":"Clinical practice guidelines for the management of sporotrichosis: 2007 update by the Infectious Diseases Society of America","volume":"45","author":"Kauffman","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.amjmed.2011.10.009_bib27","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1086\/596757","article-title":"Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America","volume":"48","author":"Pappas","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.amjmed.2011.10.009_bib28","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1086\/649858","article-title":"Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America","volume":"50","author":"Perfect","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.amjmed.2011.10.009_bib29","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1086\/525258","article-title":"Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America","volume":"46","author":"Walsh","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.amjmed.2011.10.009_bib30","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1086\/521259","article-title":"Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America","volume":"45","author":"Wheat","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.amjmed.2011.10.009_bib31","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.tim.2010.02.004","article-title":"Therapy for fungal diseases: opportunities and priorities","volume":"18","author":"Denning","year":"2010","journal-title":"Trends Microbiol"},{"key":"10.1016\/j.amjmed.2011.10.009_bib32","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1086\/504492","article-title":"Pharmacology of systemic antifungal agents","volume":"43","author":"Dodds Ashley","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.amjmed.2011.10.009_bib33","article-title":"Final results of APRICOT: A randomized, partially blinded, international trial evaluating peginterferon-a-2a + ribavirin vs. interferon-a-2a + ribavirin in the treatment of HCV in HIV\/HCV co-infection","author":"Torriani","year":"2004"},{"key":"10.1016\/j.amjmed.2011.10.009_bib34","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/s10096-005-0080-0","article-title":"Adverse effects of antifungal therapies in invasive fungal infections: review and meta-analysis","volume":"25","author":"Girois","year":"2006","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.amjmed.2011.10.009_bib35","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0030-6665(00)80005-5","article-title":"Agents for treatment of invasive fungal infections","volume":"33","author":"Luna","year":"2000","journal-title":"Otolaryngol Clin North Am"},{"key":"10.1016\/j.amjmed.2011.10.009_bib36","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1080\/13693780701730469","article-title":"Renal impairment and amphotericin B formulations in patients with invasive fungal infections","volume":"46","author":"Saliba","year":"2008","journal-title":"Med Mycol"},{"key":"10.1016\/j.amjmed.2011.10.009_bib37","series-title":"Vrend","year":"2010"},{"key":"10.1016\/j.amjmed.2011.10.009_bib38","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2165\/11585270-000000000-00000","article-title":"Echinocandin antifungal drugs in fungal infections: a comparison","volume":"71","author":"Chen","year":"2011","journal-title":"Drugs"},{"key":"10.1016\/j.amjmed.2011.10.009_bib39","first-page":"170","article-title":"Hepatotoxicity of antifungal agents","volume":"6","author":"Song","year":"2005","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1016\/j.amjmed.2011.10.009_bib40","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1182\/blood-2003-08-2644","article-title":"Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants","volume":"103","author":"Marr","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.amjmed.2011.10.009_bib41","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1517\/14656566.6.13.2231","article-title":"Drug-drug interactions of antifungal agents and implications for patient care","volume":"6","author":"Gubbins","year":"2005","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.amjmed.2011.10.009_bib42","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1128\/AAC.14.2.270","article-title":"Erythropoietin concentration in amphotericin B-induced anemia","volume":"14","author":"MacGregor","year":"1978","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.amjmed.2011.10.009_bib43","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1345\/aph.1H671","article-title":"Adverse effects of voriconazole: analysis of the French Pharmacovigilance Database","volume":"41","author":"Eiden","year":"2007","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.amjmed.2011.10.009_bib44","doi-asserted-by":"crossref","first-page":"566","DOI":"10.4269\/ajtmh.2011.10-0662","article-title":"Central nervous system toxicity associated with liposomal amphotericin B therapy for cutaneous leishmaniasis","volume":"84","author":"Glasser","year":"2011","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.amjmed.2011.10.009_bib45","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1089\/jop.2010.0046","article-title":"Persistent photopsia following course of oral voriconazole","volume":"26","author":"Kadikoy","year":"2010","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.amjmed.2011.10.009_bib46","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jaad.2009.09.033","article-title":"Chronic phototoxicity and aggressive squamous cell carcinoma of the skin in children and adults during treatment with voriconazole","volume":"62","author":"Cowen","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.amjmed.2011.10.009_bib47","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1111\/j.1469-0691.2009.03124.x","article-title":"Multiple aggressive squamous cell carcinomas associated with prolonged voriconazole therapy in four immunocompromised patients","volume":"16","author":"Epaulard","year":"2010","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.amjmed.2011.10.009_bib48","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1111\/j.1524-4725.2010.01596.x","article-title":"Catastrophic squamous cell carcinoma in lung transplant patients treated with voriconazole","volume":"36","author":"Ibrahim","year":"2010","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.amjmed.2011.10.009_bib49","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1001\/archdermatol.2009.362","article-title":"Melanoma associated with long-term voriconazole therapy: a new manifestation of chronic photosensitivity","volume":"146","author":"Miller","year":"2010","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.amjmed.2011.10.009_bib50","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/j.healun.2010.05.022","article-title":"Voriconazole exposure and geographic location are independent risk factors for squamous cell carcinoma of the skin among lung transplant recipients","volume":"29","author":"Vadnerkar","year":"2010","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.amjmed.2011.10.009_bib51","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1086\/598327","article-title":"Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents","volume":"48","author":"Bruggemann","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.amjmed.2011.10.009_bib52","series-title":"Diflucan","year":"2010"},{"key":"10.1016\/j.amjmed.2011.10.009_bib53","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/BF00199879","article-title":"Influence of concomitant food intake on the oral absorption of two triazole antifungal agents, itraconazole and fluconazole","volume":"46","author":"Zimmermann","year":"1994","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.amjmed.2011.10.009_bib54","first-page":"491","article-title":"The influence of gastric pH on the pharmacokinetics of fluconazole: the effect of omeprazole","volume":"32","author":"Zimmermann","year":"1994","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"suppl 1","key":"10.1016\/j.amjmed.2011.10.009_bib55","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1046\/j.1365-2125.2003.01999.x","article-title":"Histamine H2-receptor antagonists have no clinically significant effect on the steady-state pharmacokinetics of voriconazole","volume":"56","author":"Purkins","year":"2003","journal-title":"Br J Clin Pharmacol"},{"issue":"suppl 1","key":"10.1016\/j.amjmed.2011.10.009_bib56","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1046\/j.1365-2125.2003.01994.x","article-title":"Effect of food on the pharmacokinetics of multiple-dose oral voriconazole","volume":"56","author":"Purkins","year":"2003","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.amjmed.2011.10.009_bib57","series-title":"Sporanox capsules","year":"2009"},{"key":"10.1016\/j.amjmed.2011.10.009_bib58","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1128\/AAC.37.4.778","article-title":"Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers","volume":"37","author":"Barone","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.amjmed.2011.10.009_bib59","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/BF00558308","article-title":"The effects of food and dose on the oral systemic availability of itraconazole in healthy subjects","volume":"36","author":"Van Peer","year":"1989","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.amjmed.2011.10.009_bib60","series-title":"Noxafil","year":"2009"},{"key":"10.1016\/j.amjmed.2011.10.009_bib61","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1128\/AAC.48.3.804-808.2004","article-title":"Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men","volume":"48","author":"Courtney","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.amjmed.2011.10.009_bib62","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1128\/AAC.01034-08","article-title":"Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers","volume":"53","author":"Krishna","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.amjmed.2011.10.009_bib63","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1128\/AAC.50.5.1881-1883.2006","article-title":"Effect of a nutritional supplement on posaconazole pharmacokinetics following oral administration to healthy volunteers","volume":"50","author":"Sansone-Parsons","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.amjmed.2011.10.009_bib64","doi-asserted-by":"crossref","first-page":"211","DOI":"10.2165\/00003088-200544020-00006","article-title":"Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations","volume":"44","author":"Ezzet","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.amjmed.2011.10.009_bib65","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1128\/AAC.50.2.658-666.2006","article-title":"Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection","volume":"50","author":"Ullmann","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.amjmed.2011.10.009_bib66","series-title":"Cancidas","year":"2008"},{"key":"10.1016\/j.amjmed.2011.10.009_bib67","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1592\/phco.30.8.842","article-title":"Management of drug and food interactions with azole antifungal agents in transplant recipients","volume":"30","author":"Dodds Ashley","year":"2010","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.amjmed.2011.10.009_bib68","doi-asserted-by":"crossref","first-page":"395","DOI":"10.2174\/138920009788499012","article-title":"Drug-drug interactions of triazole antifungal agents in multimorbid patients and implications for patient care","volume":"10","author":"Nivoix","year":"2009","journal-title":"Curr Drug Metab"},{"key":"10.1016\/j.amjmed.2011.10.009_bib69","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.clpt.2004.02.002","article-title":"Pharmacokinetics of voriconazole and cytochrome P450 2C19 genetic status","volume":"75","author":"Ikeda","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.amjmed.2011.10.009_bib70","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00228-008-0574-7","article-title":"The CYP2C19 ultra-rapid metabolizer genotype influences the pharmacokinetics of voriconazole in healthy male volunteers","volume":"65","author":"Wang","year":"2009","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.amjmed.2011.10.009_bib71","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.clpt.2006.04.004","article-title":"Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir","volume":"80","author":"Mikus","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.amjmed.2011.10.009_bib72","first-page":"950","article-title":"Fungal infections in ICU patients: epidemiology and the role of diagnostics","volume":"76","author":"Morace","year":"2010","journal-title":"Minerva Anestesiol"},{"key":"10.1016\/j.amjmed.2011.10.009_bib73","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1093\/jac\/dkp464","article-title":"Safety of triazole antifungal drugs in patients with cancer","volume":"65","author":"Cronin","year":"2010","journal-title":"J Antimicrob Chemother"},{"issue":"suppl 1","key":"10.1016\/j.amjmed.2011.10.009_bib74","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1439-0507.2010.01984.x","article-title":"Posaconazole: clinical pharmacokinetics and drug interactions","volume":"54","author":"Lipp","year":"2011","journal-title":"Mycoses"},{"key":"10.1016\/j.amjmed.2011.10.009_bib75","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s00134-008-1383-2","article-title":"Mini-series: II","volume":"35","author":"Spriet","year":"2009","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.amjmed.2011.10.009_bib76","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMra052270","article-title":"Drug-related hepatotoxicity","volume":"354","author":"Navarro","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2011.10.009_bib77","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.bbmt.2009.08.015","article-title":"Hepatic safety of voriconazole after allogeneic hematopoietic stem cell transplantation","volume":"16","author":"Amigues","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.amjmed.2011.10.009_bib78","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1016\/j.clinthera.2007.09.016","article-title":"Effects of liposomal amphotericin B versus an amphotericin B lipid complex on liver histopathology in patients with hematologic malignancies and invasive fungal infections: a retrospective, nonrandomized autopsy study","volume":"29","author":"Chamilos","year":"2007","journal-title":"Clin Ther"},{"key":"10.1016\/j.amjmed.2011.10.009_bib79","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/sj.bmt.1704828","article-title":"Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients","volume":"35","author":"Trifilio","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.amjmed.2011.10.009_bib80","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1086\/524669","article-title":"Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes","volume":"46","author":"Pascual","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.amjmed.2011.10.009_bib81","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1177\/0091270005283837","article-title":"Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities","volume":"46","author":"Tan","year":"2006","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.amjmed.2011.10.009_bib82","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1128\/AAC.01657-09","article-title":"Systematic review and meta-analysis of the tolerability and hepatotoxicity of antifungals in empirical and definitive therapy for invasive fungal infection","volume":"54","author":"Wang","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.amjmed.2011.10.009_bib83","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1093\/jac\/35.5.641","article-title":"Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis","volume":"35","author":"Ruhnke","year":"1995","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.amjmed.2011.10.009_bib84","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0891-5520(02)00068-5","article-title":"Clinical pharmacology of antifungal compounds","volume":"17","author":"Groll","year":"2003","journal-title":"Infect Dis Clin North Am"},{"key":"10.1016\/j.amjmed.2011.10.009_bib85","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.2165\/00003495-200565110-00007","article-title":"Posaconazole","volume":"65","author":"Keating","year":"2005","journal-title":"Drugs"},{"key":"10.1016\/j.amjmed.2011.10.009_bib86","doi-asserted-by":"crossref","first-page":"3459","DOI":"10.1128\/AAC.00791-07","article-title":"Altered pharmacokinetics of voriconazole in a patient with liver cirrhosis","volume":"51","author":"Weiler","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.amjmed.2011.10.009_bib87","series-title":"Eraxis","year":"2009"},{"key":"10.1016\/j.amjmed.2011.10.009_bib88","series-title":"Mycamine","year":"2010"},{"key":"10.1016\/j.amjmed.2011.10.009_bib89","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1177\/0091270007303764","article-title":"Single- and multiple-dose administration of caspofungin in patients with hepatic insufficiency: implications for safety and dosing recommendations","volume":"47","author":"Mistry","year":"2007","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.amjmed.2011.10.009_bib90","article-title":"Hepatic safety of long-term exposure to caspofungin or micafungin among patients at Duke University Medical Center (DUMC)","author":"Pullaiah","year":"2010"},{"key":"10.1016\/j.amjmed.2011.10.009_bib91","series-title":"AmBisome","year":"2008"},{"key":"10.1016\/j.amjmed.2011.10.009_bib92","series-title":"Abelcet","year":"2010"},{"key":"10.1016\/j.amjmed.2011.10.009_bib93","series-title":"Amphotec","year":"2005"},{"key":"10.1016\/j.amjmed.2011.10.009_bib94","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.3201\/eid1507.090043","article-title":"Frequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failure","volume":"15","author":"Howard","year":"2009","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.amjmed.2011.10.009_bib95","doi-asserted-by":"crossref","first-page":"e219","DOI":"10.1371\/journal.pmed.0050219","article-title":"Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism","volume":"5","author":"Snelders","year":"2008","journal-title":"PLoS Med"},{"key":"10.1016\/j.amjmed.2011.10.009_bib96","doi-asserted-by":"crossref","first-page":"913","DOI":"10.2165\/00003088-200241120-00002","article-title":"Clinical significance of the cytochrome P450 2C19 genetic polymorphism","volume":"41","author":"Desta","year":"2002","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.amjmed.2011.10.009_bib97","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1177\/0091270008327537","article-title":"CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole","volume":"49","author":"Weiss","year":"2009","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.amjmed.2011.10.009_bib98","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1002\/cncr.22568","article-title":"Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients","volume":"109","author":"Trifilio","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.amjmed.2011.10.009_bib99","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa061098","article-title":"Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease","volume":"356","author":"Ullmann","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2011.10.009_bib100","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/clpt.2010.64","article-title":"Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma","volume":"88","author":"Jang","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.amjmed.2011.10.009_bib101","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1592\/phco.27.12.1627","article-title":"Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease","volume":"27","author":"Krishna","year":"2007","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.amjmed.2011.10.009_bib102","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1086\/508774","article-title":"Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial","volume":"44","author":"Walsh","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.amjmed.2011.10.009_bib103","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1056\/NEJMoa061094","article-title":"Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia","volume":"356","author":"Cornely","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2011.10.009_bib104","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1128\/AAC.00240-09","article-title":"Posaconazole therapeutic drug monitoring: a reference laboratory experience","volume":"53","author":"Thompson","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.amjmed.2011.10.009_bib105","series-title":"Agents of Mucormycosis and Entomophthoramycosis","author":"Kontoyiannis","year":"2010"},{"key":"10.1016\/j.amjmed.2011.10.009_bib106","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S1473-3099(10)70316-9","article-title":"Mucormycosis: its contemporary face and management strategies","volume":"11","author":"Sun","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.amjmed.2011.10.009_bib107","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1182\/blood-2011-03-316430","article-title":"How I treat mucormycosis","volume":"118","author":"Kontoyiannis","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.amjmed.2011.10.009_bib108","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1086\/423274","article-title":"Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole","volume":"39","author":"Imhof","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.amjmed.2011.10.009_bib109","first-page":"ECR42","article-title":"Breakthrough zygomycosis during voriconazole treatment for invasive aspergillosis","volume":"89","author":"Kobayashi","year":"2004","journal-title":"Haematologica"},{"key":"10.1016\/j.amjmed.2011.10.009_bib110","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1086\/428780","article-title":"Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases","volume":"191","author":"Kontoyiannis","year":"2005","journal-title":"J Infect Dis"},{"key":"10.1016\/j.amjmed.2011.10.009_bib111","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1056\/NEJM200402263500923","article-title":"Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants","volume":"350","author":"Marty","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2011.10.009_bib112","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1080\/00365540410019408","article-title":"Two case reports: fatal Absidia corymbifera pulmonary tract infection in the first postoperative phase of a lung transplant patient receiving voriconazole prophylaxis, and transient bronchial Absidia corymbifera colonization in a lung transplant patient","volume":"36","author":"Mattner","year":"2004","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.amjmed.2011.10.009_bib113","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1086\/427759","article-title":"Breakthrough zygomycosis during empirical voriconazole therapy in febrile patients with neutropenia","volume":"40","author":"Oren","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.amjmed.2011.10.009_bib114","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s00431-004-1606-7","article-title":"Failure of voriconazole to cure disseminated zygomycosis in an immunocompromised child","volume":"164","author":"Ritz","year":"2005","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.amjmed.2011.10.009_bib115","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1086\/422723","article-title":"Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis","volume":"39","author":"Siwek","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.amjmed.2011.10.009_bib116","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/sj.bmt.1705754","article-title":"Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole","volume":"40","author":"Trifilio","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.amjmed.2011.10.009_bib117","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/sj.bmt.1705614","article-title":"Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy","volume":"39","author":"Trifilio","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.amjmed.2011.10.009_bib118","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/bmt.2009.74","article-title":"Fatal cerebral zygomycosis breakthrough in a patient with acute lymphoblastic leukemia on voriconazole prophylaxis after cord blood SCT","volume":"44","author":"Vande Broek","year":"2009","journal-title":"Bone Marrow Transplant"},{"issue":"suppl 5","key":"10.1016\/j.amjmed.2011.10.009_bib119","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1469-0691.2009.02988.x","article-title":"Voriconazole-associated zygomycosis: a significant consequence of evolving antifungal prophylaxis and immunosuppression practices?","volume":"15","author":"Pongas","year":"2009","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.amjmed.2011.10.009_bib120","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1227\/01.NEU.0000351773.74034.5E","article-title":"A successful combined endovascular and surgical treatment of a cranial base mucormycosis with an associated internal carotid artery pseudoaneurysm","volume":"65","author":"Alvernia","year":"2009","journal-title":"Neurosurgery"},{"key":"10.1016\/j.amjmed.2011.10.009_bib121","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.1439-0507.2007.01364.x","article-title":"Rhinocerebral mucormycosis: the disease spectrum in 27 patients","volume":"50","author":"Mohindra","year":"2007","journal-title":"Mycoses"},{"issue":"suppl 5","key":"10.1016\/j.amjmed.2011.10.009_bib122","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/j.1469-0691.2009.02989.x","article-title":"Orbitomaxillary mucormycosis (zygomycosis) and the surgical approach to treatment: perspectives from a maxillofacial surgeon","volume":"15","author":"Rapidis","year":"2009","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.amjmed.2011.10.009_bib123","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1159\/000315675","article-title":"Lessons from a case of oromandibular mucormycosis treated with surgery and a combination of amphotericin B lipid formulation plus caspofungin","volume":"124","author":"Ojeda-Uribe","year":"2010","journal-title":"Acta Haematol"},{"key":"10.1016\/j.amjmed.2011.10.009_bib124","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1136\/pgmj.2003.016030","article-title":"Presentation and outcome of rhino-orbital-cerebral mucormycosis in patients with diabetes","volume":"80","author":"Bhansali","year":"2004","journal-title":"Postgrad Med J"},{"issue":"suppl 5","key":"10.1016\/j.amjmed.2011.10.009_bib125","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1469-0691.2009.02984.x","article-title":"In vitro activity of antifungals against Zygomycetes","volume":"15","author":"Alastruey-Izquierdo","year":"2009","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.amjmed.2011.10.009_bib126","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1128\/AAC.00452-07","article-title":"In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents","volume":"51","author":"Almyroudis","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.amjmed.2011.10.009_bib127","doi-asserted-by":"crossref","first-page":"3549","DOI":"10.1128\/AAC.00184-09","article-title":"In vitro interactions between antifungals and immunosuppressive drugs against zygomycetes","volume":"53","author":"Dannaoui","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.amjmed.2011.10.009_bib128","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1128\/AAC.46.5.1581-1582.2002","article-title":"In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes","volume":"46","author":"Sun","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.amjmed.2011.10.009_bib129","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1128\/AAC.46.7.2310-2312.2002","article-title":"In vivo activity of posaconazole against Mucor spp. in an immunosuppressed-mouse model","volume":"46","author":"Sun","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.amjmed.2011.10.009_bib130","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1080\/10428190310001653691","article-title":"Improved outcome of zygomycosis in patients with hematological diseases?","volume":"45","author":"Gleissner","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.amjmed.2011.10.009_bib131","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/j.1742-1241.2006.01145.x","article-title":"Mucormycosis-associated fungal infections in patients with haematologic malignancies","volume":"63","author":"Kara","year":"2009","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.amjmed.2011.10.009_bib132","first-page":"207","article-title":"Mucormycosis in hematologic patients","volume":"89","author":"Pagano","year":"2004","journal-title":"Haematologica"},{"key":"10.1016\/j.amjmed.2011.10.009_bib133","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1086\/432579","article-title":"Epidemiology and outcome of zygomycosis: a review of 929 reported cases","volume":"41","author":"Roden","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.amjmed.2011.10.009_bib134","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1093\/jac\/dkp430","article-title":"Forty-one recent cases of invasive zygomycosis from a global clinical registry","volume":"65","author":"Ruping","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.amjmed.2011.10.009_bib135","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1086\/605445","article-title":"Zygomycosis in solid organ transplant recipients: a prospective, matched case-control study to assess risks for disease and outcome","volume":"200","author":"Singh","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.amjmed.2011.10.009_bib136","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/TP.0b013e3181dde8fc","article-title":"Rhino-orbital-cerebral zygomycosis in solid organ transplant recipients","volume":"90","author":"Sun","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.amjmed.2011.10.009_bib137","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa040842","article-title":"Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients","volume":"351","author":"Torriani","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2011.10.009_bib138","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1097\/TP.0b013e3181837585","article-title":"Posaconazole as salvage therapy in patients with invasive fungal infections after solid organ transplant","volume":"86","author":"Alexander","year":"2008","journal-title":"Transplantation"},{"key":"10.1016\/j.amjmed.2011.10.009_bib139","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1128\/AAC.50.1.126-133.2006","article-title":"Posaconazole as salvage therapy for zygomycosis","volume":"50","author":"Greenberg","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.amjmed.2011.10.009_bib140","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1592\/phco.27.2.290","article-title":"Posaconazole as salvage therapy in a patient with disseminated zygomycosis: case report and review of the literature","volume":"27","author":"Page","year":"2007","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.amjmed.2011.10.009_bib141","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1053\/j.ajkd.2007.09.026","article-title":"Mucormycosis peritonitis: more than 2 years of disease-free follow-up after posaconazole salvage therapy after failure of liposomal amphotericin B","volume":"51","author":"Sedlacek","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.amjmed.2011.10.009_bib142","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1086\/375075","article-title":"Mucormycosis (zygomycosis) in a heart-kidney transplant recipient: recovery after posaconazole therapy","volume":"36","author":"Tobon","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.amjmed.2011.10.009_bib143","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1086\/500212","article-title":"Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases","volume":"42","author":"van Burik","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"suppl 5","key":"10.1016\/j.amjmed.2011.10.009_bib144","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1469-0691.2009.02985.x","article-title":"Current experience in treating invasive zygomycosis with posaconazole","volume":"15","author":"Cornely","year":"2009","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.amjmed.2011.10.009_bib145","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1093\/jac\/dkg020","article-title":"In vitro susceptibilities of zygomycetes to conventional and new antifungals","volume":"51","author":"Dannaoui","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.amjmed.2011.10.009_bib146","doi-asserted-by":"crossref","first-page":"4550","DOI":"10.1128\/AAC.00786-10","article-title":"In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella","volume":"54","author":"Pastor","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.amjmed.2011.10.009_bib147","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1128\/AAC.49.2.721-727.2005","article-title":"Caspofungin inhibits Rhizopus oryzae 1,3-\u03b2-d-glucan synthase, lowers burden in brain measured by quantitative PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis","volume":"49","author":"Ibrahim","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.amjmed.2011.10.009_bib148","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1128\/AAC.01458-07","article-title":"Combination echinocandin-polyene treatment of murine mucormycosis","volume":"52","author":"Ibrahim","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.amjmed.2011.10.009_bib149","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1086\/589857","article-title":"Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis","volume":"47","author":"Reed","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.amjmed.2011.10.009_bib150","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1128\/AAC.49.2.830-832.2005","article-title":"Combination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice","volume":"49","author":"Spellberg","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.amjmed.2011.10.009_bib151","first-page":"ECR39","article-title":"Successful treatment of rhinocerebral zygomycosis with a combination of caspofungin and liposomal amphotericin B","volume":"90","author":"Vazquez","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.amjmed.2011.10.009_bib152","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2165\/00023210-200721040-00004","article-title":"Fungal infections of the CNS: treatment strategies for the immunocompromised patient","volume":"21","author":"Black","year":"2007","journal-title":"CNS Drugs"},{"key":"10.1016\/j.amjmed.2011.10.009_bib153","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1128\/AAC.01294-09","article-title":"Micafungin concentrations from brain tissue and pancreatic pseudocyst fluid","volume":"54","author":"Lat","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.amjmed.2011.10.009_bib154","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1093\/jac\/dkq020","article-title":"In vitro interaction of posaconazole with calcineurin inhibitors and sirolimus against zygomycetes","volume":"65","author":"Narreddy","year":"2010","journal-title":"J Antimicrob Chemother"}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934311009041?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934311009041?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T08:57:19Z","timestamp":1757581039000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934311009041"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1]]},"references-count":154,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["S0002934311009041"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2011.10.009","relation":{},"ISSN":["0002-9343"],"issn-type":[{"value":"0002-9343","type":"print"}],"subject":[],"published":{"date-parts":[[2012,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Invasive Mycoses: Strategies for Effective Management","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2011.10.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}